Legal & General Group
CMPX icon

Legal & General Group’s Compass Therapeutics CMPX Stock Holding History

Legal & General Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Hold
75,103
– – ﹤0.01% 2582
2026
Q1 		$397K Buy
75,103
+62,350
+489% +$360K ﹤0.01% 2416
2025
Q4 		$68.5K Buy
12,753
+3,110
+32% +$14.4K ﹤0.01% 2672
2025
Q3 		$33.7K Hold
9,643
– – ﹤0.01% 2833
2025
Q2 		$25.1K Buy
9,643
+995
+12% +$2.05K ﹤0.01% 2917
2025
Q1 		$16.5K Sell
8,648
-1,523
-15% -$4.05K ﹤0.01% 3017
2024
Q4 		$14.7K Hold
10,171
– – ﹤0.01% 3145
2024
Q3 		$18.7K Buy
10,171
+2,761
+37% +$3.44K ﹤0.01% 3076
2024
Q2 		$7.41K Sell
7,410
-457
-6% -$667 ﹤0.01% 3346
2024
Q1 		$15.6K Sell
7,867
-13,681
-63% -$23.6K ﹤0.01% 3069
2023
Q4 		$33.6K Sell
21,548
-25,324
-54% -$43.8K ﹤0.01% 2873
2023
Q3 		$92.3K Sell
46,872
-19,627
-30% -$48.5K ﹤0.01% 2834
2023
Q2 		$211K Buy
66,499
+48,231
+264% +$151K ﹤0.01% 2730
2023
Q1 		$59.7K Buy
+18,268
New +$71.7K ﹤0.01% 2848

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group's CMPX Position: Q2 2026 in Review

Legal & General Group held its Compass Therapeutics (CMPX) position steady in Q2 2026 at 75,103 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2582.

Legal & General Group first reported a position in CMPX in Q1 2023 and has held it in 14 quarters since. The position peaked at $397K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Legal & General Group held 75,103 shares of Compass Therapeutics worth $164K as of Q2 2026.
  • Legal & General Group left its Compass Therapeutics share count unchanged in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2582 holding.
  • Legal & General Group first reported a position in Compass Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Legal & General Group's Compass Therapeutics position peaked at $397K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.